Kiyatec, a leading functional precision oncology company specializing in 3D cell culture technology and delivering evidence of therapeutic response in the oncology space, is pleased to announce that Mark Capone, former CEO of Myriad Genetics, has joined its team as a strategic advisor.
Mr. Capone is an accomplished life sciences CEO with almost 40 years of experience in molecular diagnostics, genetics, biotechnology, medical devices, and pharmaceuticals. He has extensive public and private board experience with small- to mid-cap private and public companies, trade associations, academic institutions, and nonprofits, specializing in growth and transformation of organizations.
“This is an incredible opportunity to be part of a company that is truly revolutionizing cancer care. Kiyatec’s innovative approach to personalized medicine and its commitment to improving patient outcomes are both inspiring and commendable,” said Mark Capone. “I look forward to working with the team at Kiyatec to help drive their mission forward and contribute to the advancement of cancer research and treatment.”
During his 17-year career at Myriad Genetics, Mr. Capone transformed the company from $14M revenue, 150 employees, and 1 product to a global leader in precision medicine with $850M in revenue, 3,000 employees, and 11 products, 4 of which were obtained through acquisitions deploying more than $1B in capital. Prior to joining Myriad Genetics, Mr. Capone served in a variety of roles during a 17-year career with Eli Lilly and Company including sales director, plant manager, R&D team leader, and biochemical engineer. He received his Master of Science degree in management from the Massachusetts Institute of Technology (MIT) Sloan School of Management, a Master of Science degree in (bio)chemical engineering from MIT, and a Bachelor of Science degree in chemical engineering from Penn State, graduating with highest distinction.
“Kiyatec is thrilled to have Mark Capone as a strategic advisor,” said Eric Perreault, President of Kiyatec. “His experience and knowledge about the oncology space will be invaluable. Having Mark as a sounding board to provide insights on our approach will help Kiyatec impact cancer care for years to come.”
As Kiyatec prepares for its next phase of growth and expansion, the company remains focused on advancing functional precision oncology with its 3D Predict™ platform, which provides oncologists with patient tumor-specific therapeutic response evidence within 7-10 days. And for biopharmaceutical companies developing chemotherapeutics, targeted therapies, and immuno-oncology agents for solid tumors, the KIYA-Predict™ platform accelerates and informs the preclinical development process with accurate cell response insights.
Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. They offer clinical testing for high-grade glioma and are developing tests for ovarian, breast, non-small cell lung, and rare tumors in their CLIA-certified laboratory. Kiyatec also works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors and aims to improve patient outcomes and revolutionize the field of precision medicine. For more information, visit www.Kiyatec.com.